CONCLUSIONS AND RELEVANCE Nearly 25% of men (150 of 608) electing immediate radical prostatectomy with low-volume, Gleason 3 + 4 prostate cancer on biopsy are found to harbor adverse surgical pathologic findings. These data do not support the presence of a "favorable" subgroup among included patients and could have important implications for active surveillance in similar patients with Gleason 3+4=7prostate cancer.
T he current treatment paradigm for men with localized prostate cancer involves risk stratification to distinguish men whose disease can be safely treated under active surveillance (AS) from those more likely to benefit from immediate curative intervention. 1 The National Comprehensive Cancer Network (NCCN) recommends AS as a first-line treatment option for most men diagnosed as having low-risk (LR) and very low-risk (VLR) disease based on a body of data demonstrating acceptably low rates of metastasis and prostate cancer-specific mortality over the intermediate term. 1, 2 Recent results from the ProtecT trial, which includes some men with Gleason score 7 cancer, noted similar prostate cancerspecific survival for active monitoring, surgery, and radiotherapy. 3 However, it remains unclear which subset of intermediate-risk (IR) patients with Gleason score 7 cancers can be safely treated with AS. Several groups have attempted to identify a "favorable" IR population including those with Gleason score 7 disease. The prognostic significance of pathologic grade has been demonstrated and validated to separate Gleason 3 + 4 (grade group [GG] 2) and Gleason 4 + 3 (GG3) disease in a multiinstitutional analysis. 4 Therefore, potential favorable IR cohorts have invariably been restricted to men with Gleason 3 + 4 (GG2) cancers. 5, 6 However, the original definition of favorable IR was based on survival outcomes in men treated with radiation therapy; such a population does not represent untreated patients on AS and does not allow for evaluation of true underlying pathologic abnormalities. Despite controversy, NCCN guidelines now suggest that AS may be an option for men with some IR cancers, prompting a pressing need to understand pathologic correlates and better define this risk group. 1 and LR criteria (≤T2a, PSA level <10 ng/mL). 1 For the LVIR group, clinical and pathologic factors were compared among men who did and did not have adverse pathologic findings. To identify clinically useful cut points for risk stratification, we calculated the rates of adverse pathologic findings based on various thresholds of PSA level, PSA density (PSAD), and cancer volume at diagnosis (see eMethods in the Supplement). Univariable and multivariable logistic regression analyses were performed to identify predictors of adverse pathologic findings. Akaike information criterion was evaluated for each model. Statistical analyses were performed using Stata software (version 12.0; StataCorp). 
LVIR Cohort and Predictors of Adverse Pathologic Findings
Among the 150 LVIR men with adverse surgical pathologic findings, 141 (94%) harbored disease with Gleason score of at least 4+3=7(GG≥3); only 9 additional patients were identified owing solely to seminal vesicle invasion (n = 8 [5.3%]) or lymph node positivity (n = 1 [0.7%]). Patients with and without adverse pathologic findings did not differ by age, race, family history of prostate cancer, or volume of cancer on biopsy (eTable 1intheSupplement). Stratified analyses of PSA level and PSAD revealed a consistent 2-fold difference in rate of adverse pathologic findings regardless of selected cutoffs (eTable 2 in the Supplement). Detailed stratification by cancer volume revealed no statistically significant thresholds to aid in further risk stratification (eTable 3 in the Supplement). Univariable analyses of adverse pathologic findings revealed associations with PSA level, PSAD, and year of surgery for LVIR patients ( Table 2) . Multivariable analysis of the overall cohort showed Gleason score exerted the largest effect (odds ratio, 4.30; 95% CI, 3.40-5.44; P < .001).
Discussion
Active surveillance seems to be a safe treatment option in most men with Gleason 6 (GG1) prostate cancer, but it remains unclear whether AS should be considered in the population of men with limited Gleason 3+4=7(GG2) disease. Existing literature has demonstrated that pathologic grade of at least 4+3=7 , seminal vesicle invasion, and lymph node metastasis are the strongest predictors of long-term outcomes after surgery.
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Figure. Therefore, it is reasonable to propose that a subgroup of Gleason3+4=7(GG2) cancers at minimal risk of harboring these features could be monitored with AS to avoid harms of overtreatment. Our findings, however, revealed 1 in 4 men with lowvolume Gleason 3+4=7(GG2) disease on biopsy harbored adverse surgical pathologic findings. Indeed, the rate of adverse pathologic findings was more than 4-fold higher than observed in the VLR and LR populations and remained high even when limited to all other VLR and LR criteria. Furthermore, no clinical or pathological parameters could distinguish a population of LVIR men with pathologic outcomes comparable with the VLR or LR cohorts. The goal of AS is to reduce overtreatment of prostate cancer for patients unlikely to benefit from intervention. 2 The traditional focus has been on LR disease, where urologists vary widely in selecting patients for AS and treatment. 14,15
Limitations
Limitations of the present study include the use of a retrospective cohort undergoing radical prostatectomy. However, all men were risk-stratified according to NCCN criteria, the same inclusion criteria used for our prospective AS cohort for LR and VLR men. We avoided performing survival analyses in treated men, which can bias conclusions, and instead used a validated pathologic surrogate. Another limitation of the study is that magnetic resonance imaging and molecular and/or genetic tests were not performed routinely enough to include in analyses that could further stratify patients. Finally, the analysis is limited to 1 institution with dedicated expert genitourinary pathologists.
Conclusions
Approximately 1 in 4 men with low-volume, Gleason 3+4=7 (GG2) prostate cancer on biopsy undergoing prostatectomy were found to harbor adverse pathologic findings. 
